Could supplements be the next big opportunity in the GLP-1 weight-loss drug boom?

Novonesis chief executive Ester Baiget says scientifically supported supplements could complement GLP-1 weight-loss medicines by helping patients feel better during treatment and supporting longer-term health. The company is studying microbiome products for people taking these drugs, as supplement makers look to meet demand created by the medicines’ popularity.

The study with Novo Nordisk is examining a combination of probiotics, prebiotics and postbiotics. Baiget said the approach focuses on the gut microbiome, the community of microorganisms living in and on the body, and argued that nutrition and supplements may have a role alongside obesity treatment. The article gives no study results or specific figures.